La chaîne d'options affiche les données clés des options sur actions de Enlight Renewable Energy à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Enlight Renewable Energy..

Enlight Renewable Energy (NASDAQ:ENLT) Stock, Chaîne d'Options

Enlight Renewable Energy

Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.

Enlight Renewable Energy Ltd. - Ordinary Shares

Enlight Renewable Energy Ltd

<h2>Transaction Value Of $203M &nbsp;</h2>

WIIM

OPOF

Old Point Financial shares are trading higher after the company agreed to be acquired by TowneBank for an aggregate transaction value of $203 million.

Shares of consumer packaged goods company Conagra Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) traded lower in premarket on Thursday after the third-quarter FY25 earnings.
The company reported a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44624847/conagra-brands-reports-third-quarter-results" rel="noreferrer noopener">third-quarter sales decline of 6.3%</a> year-on-year to $2.84 billion, missing the analyst consensus estimate of $2.903 billion.
Organic net sales decreased 5.2%, driven by a&nbsp;2.1% negative impact from&nbsp;price/mix and a&nbsp;3.1%&nbsp;decrease in volume.&nbsp;
Adjusted EPS of $0.51 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the consensus</a> estimate of $0.53.
Gross profit declined 17.3% to&nbsp;$710 million and the gross margin contracted 331 basis points to 25%.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44613645/levis-q1-to-see-eps-growth-revenue-dip-and-tariff-edge-says-analyst" rel="noreferrer noopener">Levi&#8217;s Q1 To See EPS Growth, Revenue Dip, And Tariff Edge, Says Analyst</a>
Selling, general, and administrative expense, which includes advertising and promotional expense, increased 14.5% to&nbsp;$444 million in the quarter.
The operating margin contracted 712 basis points to 8.4%.
The operating cash flow for nine months totaled $1.3 billion with a free cash flow of $1 billion. The company held $49.4 million in cash and equivalents as of February 23, 2025.
The company ended the quarter with net debt of&nbsp;$8.1 billion, representing a 5.9% reduction Y/Y.
&#8220;Our third quarter unfolded largely as expected since our update in February at CAGNY, with strong consumption trends and share performance reflecting the continued resilience of our brands,&#8221; said President and CEO Sean Connolly.
&#8220;While shipments lagged consumption largely due to the discrete supply constraints we announced in February, we are making solid progress in restoring inventory and improving customer service levels.&#8221;&nbsp;
Outlook Reaffirmed: Conagra sees FY25 organic net sales to decline 2%. The company expects adjusted EPS of approximately $2.35, <a href="https://www.benzinga.com/calendars/guidance">matching the consensus estimate.</a>
Price Action: CAG shares traded lower by 1.59% at $25.96 in premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/04/44603254/amc-expands-premium-movie-experience-with-imax-laser-upgrades-in-landmark-deal" target="_blank" rel="noreferrer noopener">AMC Expands Premium Movie Experience With IMAX Laser Upgrades In Landmark Deal</a></li>
</ul>
Photo by MDV Edwards via Shutterstock.

Earnings

Equities

Large Cap

News

Guidance

Movers

General

Act II Popcorn Maker Conagra Brands Q3 Profit Falls As Supply Constraints Bite

Piper Sandler analyst Brian Mullan maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NASDAQ">YUM</a>) with a Neutral and raises the price target from $140 to $150.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Corcept Therapeutics, Raises Price Target to $150

JP Morgan analyst Vivek Juneja maintains KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) with a Neutral and lowers the price target from $18.5 to $16.5.

JP Morgan Maintains Neutral on KeyCorp, Lowers Price Target to $16.5

Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Overweight and raises the price target from $128 to $131.

CORT

Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $131

CASI

CASI Pharmaceuticals shares are trading higher after the company received a $20 million proposal from CEO Dr. Wei-Wu He to acquire its business operations in China.

On Thursday, Acuity Brands, Inc&nbsp;(NYSE:&nbsp;AYI)&nbsp;reported fiscal second-quarter 2025 net sales growth of 11.1% year over year to $1.01 billion, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44623467/acuity-reports-fiscal-2025-second-quarter-results" rel="noreferrer noopener">analyst consensus estimate of $1.03 billion</a>.&nbsp;
It clocked an adjusted EPS of $3.73, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings'" rel="noreferrer noopener">analyst consensus estimate of $3.70</a>.
Sales by segments:&nbsp;Acuity Brands Lighting (ABL) revenue hit $840.6 million (-0.3% Y/Y), and Acuity Intelligent Spaces (AIS) clocked $171.5 million (+151.8% Y/Y).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/market-summary/25/04/44623604/us-stock-likely-to-open-lower-following-trumps-tariffs-worse-than-the-worst-case-scenario-says-analyst" rel="noreferrer noopener">US Stocks Likely To Open Lower Following Trump&#8217;s Tariffs: &#8216;Worse Than The Worst Case Scenario,&#8217; Says Analyst</a>
The consolidated adjusted operating margin grew by 70 bps to 16.2%. ABL's adjusted operating margin improved by 60 bps to 16.8%. AIS' margin decreased by 230 bps to 18.7%.
The company generated $191.6 million in operating cash flow for the first six months of fiscal year 2025, compared to $292.6 million a year ago. Free cash flow was $163 million.
Acuity held cash and equivalents of $397.9 million, compared to $578.9 million last year.
Adjusted EBITDA was $176.6 million, up from $153.0 million a year ago.&nbsp;The margin expanded by 60 bps to 17.5%.
Price Action:&nbsp;AYI stock closed higher by 1.04% at $266.40 at Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44613775/tradeweb-nasdaq-virtu-ice-bgc-group-cboe-set-to-benefit-from-ipo-comeback-and-market-volatility-analyst-says" target="_blank" rel="noreferrer noopener">Tradeweb, Nasdaq, Virtu, ICE, BGC Group, Cboe Set To Benefit From IPO Comeback: Analyst</a></li>
</ul>
Photo: Shutterstock

Acuity Brands Q2 Earnings: Tops EPS Estimates, Intelligent Spaces Sales Surge Over 150%, Grows Margins, EBITDA Despite Cash Flow Decline And Sales Miss

Markets

Trading Ideas

ETFs

ACWI

SPDR Dow Jones Industrial Average ETF Trust

The American Association of Individual Investors (AAII) Weekly Survey Hit A Bearish Score Of 61.9%, A 16-Year High From March 2009.

Mizuho analyst John Roberts upgrades Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Neutral to Outperform and maintains the price target from $105 to $105.

Upgrades

Mizuho Upgrades Eastman Chemical to Outperform, Maintains Price Target to $105

Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR&#x2122; and ADAPTIR-FLEX&#x2122; platform technologies, announced today that it has entered into definitive securities purchase agreements for the purchase and sale of 1,764,710 shares of the Company's common stock in a registered direct offering and warrants to purchase up to 3,529,420 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering") at a combined purchase price of $1.19 per share and accompanying warrant. The warrants issued pursuant to the concurrent private placement will have an exercise price of $1.19 per share, will be exercisable upon the receipt of shareholder approval following the date of issuance and will expire 5 years from the initial exercise date. The offering is expected to close on or about April 4, 2025 subject to the satisfaction of customary closing conditions.
Roth Capital Partners is acting as the exclusive placement agent for the offering.
Aptevo expects the gross proceeds from the offering to be approximately $2.1 million, before deducting the placement agent's fees and other estimated offering expenses payable by the Company. Aptevo intends to use the net proceeds from the proposed offering for the continued clinical development of its product candidates, working capital, and other general corporate purposes.

Offerings

APVO

Aptevo Therapeutics Has Entered Into Definitive Securities Purchase Agreements For The Purchase And Sale Of 1,764,710 Shares Of Common Stock In A Registered Direct Offering And Warrants To Purchase Up To 3,529,420 Shares Of Common Stock In A Concurrent Private Placement At A Combined Purchase Price Of $1.19 Per Share

Contracts

INTJ

Intelligent Group Ltd: Unit Intelligent Joy Ltd Signs MOU With Smart IR & CLS Press To Collaborate On Ai-Driven Investor Relations Platform

JP Morgan analyst Andrew Dietrich maintains M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Neutral and lowers the price target from $212.5 to $186.5.

JP Morgan Maintains Neutral on M&T Bank, Lowers Price Target to $186.5

Morgan Stanley analyst Simeon Gutman maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Overweight and lowers the price target from $530 to $300.

Morgan Stanley Maintains Overweight on RH, Lowers Price Target to $300

NIVF

NewGenIvf Group shares are trading higher after the company announced it secured $5.2 million in funding to drive international expansion.

Morgan Stanley analyst James Faucette upgrades Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from Equal-Weight to Overweight and raises the price target from $65 to $67.

Morgan Stanley Upgrades Block to Overweight, Raises Price Target to $67

JP Morgan analyst Andrew Dietrich maintains Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Overweight and lowers the price target from $18.5 to $16.

HBAN

JP Morgan Maintains Overweight on Huntington Bancshares, Lowers Price Target to $16

Morgan Stanley analyst Kristine Liwag upgrades Loar Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) from Equal-Weight to Overweight and maintains the price target from $91 to $91.

LOAR

Morgan Stanley Upgrades Loar Holdings to Overweight, Maintains Price Target to $91

As of April 3, 2025, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Dole PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOLE#NYSE">DOLE</a>)</h3>
<ul>
<li>On Feb. 26, Dole posted better-than-expected fourth-quarter financial results. The company's stock gained around 5% over the past five days and has a 52-week high of $17.12.</li>
<li>RSI Value: 71.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>DOLE Price Action: Shares of Dole gained 1.1% to close at $14.66 on Wednesday.</li>
<li>Edge Stock Ratings: 75.90 Momentum score with Value at 85.83. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/dole"><img loading="lazy" decoding="async" width="441" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03043731/image-1-7.png" alt="" class="wp-image-854816" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03043731/image-1-7.png 441w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03043731/image-1-7-300x120.png 300w" sizes="(max-width: 441px) 100vw, 441px" /></a></figure>
<h3 class="wp-block-heading">Adecoagro SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>)</h3>
<ul>
<li>On March 27, Adecoagro announced a deal with Tether Investments, under which Tether will launch a tender offer to acquire a majority stake in the South American agribusiness at $12.41 per share. Adecoagro CEO and Co-Founder Mariano Bosch said, "I am very excited about this transaction and the opportunity to have a significant shareholder like Tether, who shares the entrepreneurial spirit that led us to create Adecoagro 23 years ago and that continues to be present in our day-to-day decisions." The company's stock gained around 5% over the past month and <a href="https://www.benzinga.com/quote/AGRO">has a 52-week high</a> of $12.08.</li>
<li>RSI Value: 73.5</li>
<li>AGRO Price Action: Shares of Adecoagro gained 0.1% to close at $11.36 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Lifeway Foods Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>)</h3>
<ul>
<li>On March 14, Lifeway Foods posted weaker-than-expected quarterly results. &#8220;I am pleased to report another record year of net sales for Lifeway, spearheaded by the continued, strong volume growth of our flagship drinkable Lifeway Kefir,&#8221; commented Julie Smolyansky, President and Chief Executive Officer of Lifeway. The company's stock gained around 19% over the past month and has a <a href="https://www.benzinga.com/quote/LWAY">52-week high</a> of $28.61.</li>
<li>RSI Value: 74.6</li>
<li>LWAY Price Action: Shares of Lifeway Foods gained 0.6% to close at $24.84 on Wednesday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44604078/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks With Over 6% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

AGRO

DOLE

LWAY

Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs

Keefe, Bruyette &amp; Woods analyst Ryan Tomasello maintains Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) with a Outperform and lowers the price target from $40 to $28.

NCNO

Keefe, Bruyette & Woods Maintains Outperform on Ncino, Lowers Price Target to $28

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Ladenburg Thalmann analyst Christopher Nolan downgraded the rating for Sachem Capital Corp. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) from Buy to Neutral. Sachem Cap shares closed at $1.11 on Wednesday. <a href="https://www.benzinga.com/quote/SACH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Steven Zaccone downgraded the rating for Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) from Buy to Neutral and lowered the price target from $93 to $70. Best Buy shares closed at $75.73 on Wednesday. <a href="https://www.benzinga.com/quote/BBY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Craig Siegenthaler downgraded AllianceBernstein Holding L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) from Buy to Neutral and cut the price target from $42 to $38. AllianceBernstein shares closed at $39.01 on Wednesday. <a href="https://www.benzinga.com/quote/AB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Steven Zaccone downgraded the rating for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from Buy to Neutral and slashed the price target from $437 to $200. RH shares closed at $249.35 on Wednesday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying BBY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03084343/image-36-1024x599.png" alt="" class="wp-image-855360" style="width:559px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03084343/image-36-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03084343/image-36-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03084343/image-36-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03084343/image-36.png 1086w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

SACH

This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Press Releases

The Atrisco Solar & Storage Project Has Achieved Full Commercial Operations

Financing

Enlight Announces the Financial Close for Project Roadrunner

Harel and Amitim to Acquire 44% of a Partnership Holding a Cluster of Enlight Projects Comprising 69 MW Solar Generation and 448 MWh of Energy Storage Capacity

Enlight to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 19, 2025

Two Enlight Facilities Win Bids in the Israel Electricity Authority's Energy Storage Tender and the Company Expects to Construct Total Storage Capacity in the Range of 1,300 to 1,900 MWh

Comments

Enlight Renewable Energy

Enlight Renewable Energy (ENLT) Options

Enlight Renewable Energy (NASDAQ:ENLT) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL